Works matching IS 03407004 AND DT 2010 AND VI 59 AND IP 4

Results: 15

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 609, doi. 10.1007/s00262-009-0788-2

By:

Janetzki, Sylvia;
Price, L.;
Britten, C. M.;
van der Burg, S. H.;
Caterini, J.;
Currier, J. R.;
Ferrari, G.;
Gouttefangeas, C.;
Hayes, P.;
Kaempgen, E.;
Lennerz, V.;
Nihlmark, K.;
Souza, V.;
Hoos, A.

Publication type:

Article

FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 575, doi. 10.1007/s00262-009-0775-7

By:

Rolin, Johannes;
Sand, Kristin L.;
Knudsen, Eirunn;
Maghazachi, Azzam A.

Publication type:

Article

Type I interferons inhibit the generation of tumor-associated macrophages.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 587, doi. 10.1007/s00262-009-0776-6

By:

U'Ren, Lance;
Guth, Amanda;
Kamstock, Debra;
Dow, Steven

Publication type:

Article

Homeostasis of peripheral FoxP3+ CD4+ regulatory T cells in patients with early and late stage breast cancer.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 599, doi. 10.1007/s00262-009-0780-x

By:

Rech, Andrew J.;
Mick, Rosemarie;
Kaplan, David E.;
Kyong-Mi Chang;
Domchek, Susan M.;
Vonderheide, Robert H.

Publication type:

Article

Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 541, doi. 10.1007/s00262-009-0771-y

By:

Ginzkey, Christian;
Eicker, Sven O.;
Marget, Matthias;
Krause, Joerg;
Brecht, Stephan;
Westphal, Manfred;
Hugo, Hans H.;
Mehdorn, H. M.;
Steinmann, Joerg;
Hamel, Wolfgang

Publication type:

Article

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 553, doi. 10.1007/s00262-009-0773-9

By:

Passalacqua, Rodolfo;
Buzio, Carlo;
Buti, Sebastiano;
Porta, Camillo;
Labianca, Roberto;
Pezzuolo, Debora;
Camisa, Roberta;
Sabbatini, Roberto;
Benecchi, Luigi;
Messina, Caterina;
Cengarle, Rita;
Vaglio, Augusto;
Dalla Chiesa, Matteo;
Tomasello, Gianluca;
Caminiti, Caterina

Publication type:

Article

Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 563, doi. 10.1007/s00262-009-0774-8

By:

Verma, Bhavna;
Hawkins, Oriana E.;
Neethling, Francisca A.;
Caseltine, Shannon L.;
Largo, Sherly R.;
Hildebrand, William H.;
Weidanz, Jon A.

Publication type:

Article

A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 519, doi. 10.1007/s00262-009-0768-6

By:

Grille, Sofía;
Brugnini, Andreína;
Nese, Martha;
Corley, Esteban;
Falkenberg, Frank W.;
Lens, Daniela;
Chabalgoity, José A.

Publication type:

Article

CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages I–III melanoma patients.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 511, doi. 10.1007/s00262-009-0766-8

By:

Napolitano, Maria;
Ottaiano, Alessandro;
Mauro, Francesca;
Ieranò, Caterina;
Satriano, Rocco;
Pacelli, Roberto;
Franco, Renato;
De Angelis, Valentina;
Castello, Giuseppe;
Scala, Stefania

Publication type:

Article

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 529, doi. 10.1007/s00262-009-0769-5

By:

Seliger, Barbara;
Stoehr, Robert;
Handke, Diana;
Mueller, Anja;
Ferrone, Soldano;
Wullich, Bernd;
Tannapfel, Andrea;
Hofstaedter, Ferdinand;
Hartmann, Arndt

Publication type:

Article

Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 629, doi. 10.1007/s00262-009-0805-5

By:

Popmihajlov, Zoran;
Santori, Fabio R.;
Gebreselassie, Daniel;
Sandler, Anthony D.;
Vukmanovic, Stanislav

Publication type:

Article

Regulation of immunity and oncogenesis by the IRF transcription factor family.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 489, doi. 10.1007/s00262-009-0804-6

By:

Savitsky, David;
Tamura, Tomohiko;
Yanai, Hideyuki;
Taniguchi, Tadatsugu

Publication type:

Article

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 619, doi. 10.1007/s00262-009-0814-4

By:

Mander, A.;
Gouttefangeas, C.;
Ottensmeier, C.;
Welters, M. J. P.;
Low, L.;
van der Burg, S. H.;
Britten, C. M.

Publication type:

Article

Erratum to: A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.

Published in:

2010

By:

Jianxin Dai;
Bohua Li;
Jinping Shi;
Ling Peng;
Dapeng Zhang;
Weizhu Qian;
Sheng Hou;
Lei Zhao;
Jie Gao;
Zhiguo Cao;
Jian Zhao;
Hao Wang;
Yajun Guo

Publication type:

Correction Notice

ESCII–PIVAC meeting “Recent advances in cancer immunotherapy with an emphasis on cancer vaccines” held in Athens, 9–11 October 2008.

Published in:

Cancer Immunology, Immunotherapy, 2010, v. 59, n. 4, p. 635, doi. 10.1007/s00262-009-0664-0

By:

Umansky, Viktor;
Guinn, Barbara-ann

Publication type:

Article

Works matching IS 03407004 AND DT 2010 AND VI 59 AND IP 4

Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells.

FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release.

Type I interferons inhibit the generation of tumor-associated macrophages.

Homeostasis of peripheral FoxP3<sup>+</sup> CD4<sup>+</sup> regulatory T cells in patients with early and late stage breast cancer.

Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.

Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer.

Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.

A B-cell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells.

CD4<sup>+</sup>CD45RA<sup>+</sup>CXCR4<sup>+</sup> lymphocytes are inversely associated with progression in stages I–III melanoma patients.

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells.

Regulation of immunity and oncogenesis by the IRF transcription factor family.

Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.

Erratum to: A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo.

ESCII–PIVAC meeting “Recent advances in cancer immunotherapy with an emphasis on cancer vaccines” held in Athens, 9–11 October 2008.